Business
Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Highlights
Gvoke® net sales were $2.0 million in Q2 2020 Gvoke PFS prescriptions grew 72% quarter over quarter July availability of Gvoke HypoPen™ accelerates
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\nGvoke® net sales were $2.0 million in Q2 2020\n\n\nGvoke PFS prescriptions grew 72% quarter over quarter\n\n\nJuly availability of Gvoke HypoPen™ accelerates prescription growth\n\n\nJune capital raise significantly strengthens balance sheet\n\n\nCompany to host a conference call and webcast today at 8:30 a.m. ET\n\n CHICAGO--(BUSINESS WIRE)--\nXeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced financial results for the second quarter and six months ended June 30, 2020, as well as pipeline and corporate highlights.\n\n\n“Our strong performance this quarter reflects Xeris’ dedication to the communities we serve, despite numerous pandemic-related constraints. Prescriptions for Gvoke have continued to rise steadily, illustrating its utility for individuals with diabetes and their families, particularly in the current environment. We've taken thoughtful approaches to maintain continuity and deliver on our mission, including intense preparations for the launch of the Gvoke HypoPen, which was announced just weeks ago, positive results from four of our clinical development programs, and a successful capital raise that strengthens our balance sheet,\" said Paul R. Edick, Chairman and Chief Executive Officer. \"We're very proud of what we've accomplished so far this year, despite the circumstances, and are building on our momentum with the recent Gvoke HypoPen launch that has already accelerated prescription growth, recent and upcoming regulatory dialogue around our clinical programs, and an anticipated European regulatory decision for our ready-to-use glucagon application later this year or early next year.\"\n\n\nSecond Quarter 2020 Highlights and Recent Events\n\n\nGvoke®\n\n\n\nIn May, Xeris extended its $0 copay for Gvoke PFS to relieve the financial burden for commercially insured patients during the COVID-19 pandemic.\n\n\nGvoke PFS prescriptions grew 72% quarter over quarter.\n\n\nIn July, Xeris launched its Gvoke HypoPen™ and implemented a $0 copay offer for commercially insured patients.\n\n\nCurrently, approximately 80% of patients have unrestricted access to Gvoke (PFS and HypoPen) across all payers.\n\n\n\nPipeline Programs\n\n\n\nIn Ju...